Rituximab biosimilar (Nichi-Iko/Aprogen)

利妥昔单抗生物类似药 (Nichi-Iko/Aprogen)

Report date: 2022/03/16 10:15:02

Base Information

Drug NameRituximab biosimilar (Nichi-Iko/Aprogen)
Drug Alias NameRituximab biosimilar (Nichi-Iko/Aprogen)利妥昔单抗生物仿制药 (Nichi-Iko Pharmaceutical/Aprogen)Rituximabum biosimilar(Nichi-Iko/Aprogen)Rituximab-EU biosimilar(Nichi-Iko/Aprogen)AP-056 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesAprogenNichi-Iko Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAprogenNichi-Iko Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationAutoimmune DiseasesLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC02
Related LinksN/A